CRISPR Therapeutics
CRSP
CRSP
257 hedge funds and large institutions have $1.51B invested in CRISPR Therapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 97 increasing their positions, 54 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
2% more funds holding
Funds holding: 253 → 257 (+4)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
22% less capital invested
Capital invested by funds: $1.92B → $1.51B (-$416M)
Holders
257
Holding in Top 10
5
Calls
$41.5M
Puts
$31.8M
Top Buyers
| 1 | +$56.4M | |
| 2 | +$30.4M | |
| 3 | +$25.3M | |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$15.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$14.7M |
Top Sellers
| 1 | -$19M | |
| 2 | -$15.7M | |
| 3 | -$9.74M | |
| 4 |
O
OrbiMed
New York
|
-$9.13M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.79M |